The first VAP-1 targeted PET tracer [68Ga]Ga-DOTA-Siglec-9 has finally entered in clinical trials. Sofar, two healthy volunteers have successfully been imaged at Turku PET Centre. (ClinicalTrials.gov Identifier: NCT03755245: Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis (SIGLEC))
The first VAP-1 targeted PET tracer [68Ga]Ga-DOTA-Siglec-9 has finally entered in clinical trials at Turku PET Centre.
